Aim: To assess the role of stereotactic body radiotherapy (SBRT) in pulmonary metastases from colorectal cancer (CRC). Patients and Methods: Thirty-three consecutive patients with pulmonary metastases from CRC who received SBRT were included in the analysis. The primary endpoints were local and systemic progression-free survival, a secondary endpoint was the safety profile of SBRT. Results: A total of 56 lesions were treated with SBRT. A single nodule was treated in 15 patients, two in 13 and three in five. The radiotherapy dose and the adopted fractionations were 24-27 Gy as a single fraction for 40 lesions and 27-42 Gy in three fractions (2-3 times a week) for the other 16 lesions. After a median follow-up of 22.8 months (range=1.3-45.7 months), the median progressionfree survival of the irradiated sites was 13.4 months. Conclusion: SBRT can be considered as local therapy in patients with lung metastases from CRC.

Stereotactic body radiotherapy in patients with lung oligometastases from colorectal cancer

Pasqualetti, Francesco;Montrone, Sabrina;Vivaldi, Caterina;Fedele, David;Pasqualetti, Giuseppe;Salvatore, Lisa;Coraggio, Gabriele;Gonnelli, Alessandra;Loupakis, Fotios;Masi, Gianluca;Monzani, Fabio;Falcone, Alfredo;Paiar, Fabiola
2017

Abstract

Aim: To assess the role of stereotactic body radiotherapy (SBRT) in pulmonary metastases from colorectal cancer (CRC). Patients and Methods: Thirty-three consecutive patients with pulmonary metastases from CRC who received SBRT were included in the analysis. The primary endpoints were local and systemic progression-free survival, a secondary endpoint was the safety profile of SBRT. Results: A total of 56 lesions were treated with SBRT. A single nodule was treated in 15 patients, two in 13 and three in five. The radiotherapy dose and the adopted fractionations were 24-27 Gy as a single fraction for 40 lesions and 27-42 Gy in three fractions (2-3 times a week) for the other 16 lesions. After a median follow-up of 22.8 months (range=1.3-45.7 months), the median progressionfree survival of the irradiated sites was 13.4 months. Conclusion: SBRT can be considered as local therapy in patients with lung metastases from CRC.
Pasqualetti, Francesco; Montrone, Sabrina; Vivaldi, Caterina; Zani, Margherita; Fedele, David; Fornaro, Lorenzo; Pasqualetti, Giuseppe; Salvatore, Lisa; Manfredi, Bruno; Laliscia, Concetta; Coraggio, Gabriele; Gonnelli, Alessandra; Loupakis, Fotios; Masi, Gianluca; Sainato, Aldo; Monzani, Fabio; Falcone, Alfredo; Paiar, Fabiola
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11568/914683
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 21
social impact